Pyridopyrimidines methods for their preparation and pharmaceutical formulations thereof
申请人:THE WELLCOME FOUNDATION LIMITED
公开号:EP0278686A1
公开(公告)日:1988-08-17
The present invention relates to compounds of the general formula (III)
wherein R¹ is hydrogen when R² is methyl or R¹ is methyl when R² is hydrogen, and pharmaceutically acceptable salts thereof, i.e. the compounds 2,4-diamino-5-methyl-6-(2-hydroxy-5-methoxybenzyl)pyrido (2,3-d)pyrimidine and 2,4-diamino-5-methyl-6-(5-hydroxy-2-methoxybenzyl)pyrido(2,3-d)pyrimidine and their pharmaceutically acceptable salts.
The compounds have potent inhibitory activity against dihydrofolate reductase, and are useful in treating bacterial infections and in treating proliferative diseases, for example in mammals.
Compounds of formula (III) may be prepared for example by debenzylation of the corresponding benzyloxy derivative.
本发明涉及一般式(III)的化合物,其中当R²为甲基时,R¹为氢,或当R²为氢时,R¹为甲基,以及其药学上可接受的盐,即2,4-二氨基-5-甲基-6-(2-羟基-5-甲氧基苯基)吡啶(2,3-d)嘧啶和2,4-二氨基-5-甲基-6-(5-羟基-2-甲氧基苯基)吡啶(2,3-d)嘧啶及其药学上可接受的盐。该化合物具有对二氢叶酸还原酶的强抑制活性,并可用于治疗细菌感染和治疗增殖性疾病,例如在哺乳动物中。例如,可以通过脱苄基化相应的苄氧衍生物来制备式(III)的化合物。